Skip to main content
Lyndsay Harris, MD, Oncology, Bethesda, MD, University Hospitals Cleveland Medical Center

LyndsayNorineHarrisMD

Oncology • Bethesda, MD

Breast Cancer, Clinical Informatics

Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI

Join to view full profile

Dr. Harris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Harris' full profile

Already have an account?

Summary

  • Dr. Lyndsay Harris is a medical oncologist in in the Cancer Diagnosis Program at the National Cancer Institute. She received her medical degree from University of Alberta Faculty of Medicine and her Fellowship at Georgetown University. She has been in practice 35 years. She specializes in breast cancer and clinical informatics and is experienced in biomarkers and assays, molecular biology and genomics

Education & Training

  • Georgetown University Hospital
    Georgetown University HospitalFellowship, Medical Oncology, 1991 - 1994
  • University of Alberta
    University of AlbertaClass of 1988

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2024
  • CT State Medical License
    CT State Medical License 2006 - 2012

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor  
    Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
  • The Challenge for Development of Valuable Immuno-Oncology Biomarkers  
    Arta M Monjazeb, Janice M Mehnert, Lyndsay N Harris, Clinical Cancer Research

Press Mentions

  • NCI-MATCH Cancer Trial Finds a Promising Signal for the AKT Inhibitor Ipatasertib
    NCI-MATCH Cancer Trial Finds a Promising Signal for the AKT Inhibitor IpatasertibOctober 26th, 2022
  • ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as It Continues to Locate Patients with BRAF Mutations
    ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as It Continues to Locate Patients with BRAF MutationsMarch 16th, 2022
  • 12 Open Arms in NCI-MATCH Treatment Trial Await Patients with Advanced or Rare Cancers
    12 Open Arms in NCI-MATCH Treatment Trial Await Patients with Advanced or Rare CancersApril 26th, 2021
  • Join now to see all

Grant Support

  • Targeted Combinations For Her2- Positive Breast Cancer BiologyNational Cancer Institute2008–2009
  • P-2: Target Combinations For HER2 - Positive Breast CancerNational Cancer Institute2005–2007
  • Core--Tissue And PathologyNational Cancer Institute2000–2002
  • Erbb2/P53 And Taxane Chemotherapy For Breast CancerNational Cancer Institute1999–2000

Committees

  • Co-chair, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present

Professional Memberships

Hospital Affiliations

Dr. Lyndsay Harris, Dr. Lyndsay Harris, MD, Dr. L Harris, Dr. Lyndsay Norine Harris